FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2262585804> ?p ?o ?g. }

• W2262585804 endingPage "8" @default.
• W2262585804 startingPage "1011" @default.
• W2262585804 abstract "Polycythemia vera (PV) is a myeloproliferative disorder, characterized by the expansion of the red cell mass. Our purpose was to evaluate the efficacy of pipobroman (PB) in the long-term control of PV and to assess early and late events.From June 1975 to December 1997, 163 untreated patients with PV (median age 57 years, range 30-82) were treated with PB in a single Institute for a median follow-up of 120 months. The diagnosis was made according to the Polycythemia Vera Study Group criteria. PB was given at the dose of 1 mg/kg/day until hematologic response (hematocrit < 45% and platelets < 400x109/L) and of 0.3-0.6 mg/kg/day as maintenance therapy.Hematologic remission was achieved in 94% of patients in a median time of 13 weeks (range 6-48). Median overall survival was 215 months, with a standardized mortality ratio of 1.7. The cumulative risk of death was 11%, 22%, and 26% at 7, 10, and 12 years, respectively. The incidence of thrombotic events was 18.4x105 person-year and the cumulative risk was 6%, 11%, 16%, and 20% at 3, 7, 10, and 12 years respectively. Acute leukemia occurred in 11 patients, myelofibrosis in 7, and solid tumors in 11. The 10-year cumulative risk of leukemia, myelofibrosis, and solid tumors was 5%, 4%, and 8%, respectively. In the logistic analysis age over 65 (p = 0.0001) and thrombotic events at diagnosis (p = 0.001) were significantly correlated with a higher risk of death. Female gender (p = 0.02) and age over 65 (p = 0.01) significantly influenced the occurrence of thrombotic complications. Age was the only significant risk factor for leukemia (p = 0.04) and for solid tumors (p = 0.03), while the duration of PB treatment did not influence these risks. No significant risk factor was demonstrated for myelofibrosis.This study demonstrates in a large series of patients, observed for a long period, that pipobroman is effective in the long-term control of PV. The risk of early thrombotic complications at 3 years is 6% and the 10-year risk of acute leukemia, late myelofibrosis, and solid tumors is 5%, 4%, and 8%, respectively. The duration of pipobroman treatment did not correlate with these events." @default.
• W2262585804 created "2016-06-24" @default.
• W2262585804 creator A5008633354 @default.
• W2262585804 creator A5009381933 @default.
• W2262585804 creator A5011435773 @default.
• W2262585804 creator A5017814449 @default.
• W2262585804 creator A5021045480 @default.
• W2262585804 creator A5045043807 @default.
• W2262585804 creator A5048644406 @default.
• W2262585804 creator A5060211572 @default.
• W2262585804 creator A5077344066 @default.
• W2262585804 creator A5078109432 @default.
• W2262585804 date "2000-10-01" @default.
• W2262585804 modified "2023-10-16" @default.
• W2262585804 title "Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients." @default.
• W2262585804 cites W125905140 @default.
• W2262585804 cites W1446966563 @default.
• W2262585804 cites W1513929198 @default.
• W2262585804 cites W1548342317 @default.
• W2262585804 cites W168904253 @default.
• W2262585804 cites W1928343029 @default.
• W2262585804 cites W1986623762 @default.
• W2262585804 cites W2029353341 @default.
• W2262585804 cites W2032801230 @default.
• W2262585804 cites W2039687934 @default.
• W2262585804 cites W2070333384 @default.
• W2262585804 cites W2072691059 @default.
• W2262585804 cites W2076259108 @default.
• W2262585804 cites W2077812003 @default.
• W2262585804 cites W2087946529 @default.
• W2262585804 cites W2099165047 @default.
• W2262585804 cites W2117054170 @default.
• W2262585804 cites W2132723766 @default.
• W2262585804 cites W2142864556 @default.
• W2262585804 cites W2150113701 @default.
• W2262585804 cites W2171735954 @default.
• W2262585804 cites W2213345967 @default.
• W2262585804 cites W2317624320 @default.
• W2262585804 cites W2337577525 @default.
• W2262585804 cites W2341264142 @default.
• W2262585804 cites W2399669199 @default.
• W2262585804 cites W2415359808 @default.
• W2262585804 cites W46453237 @default.
• W2262585804 cites W53178620 @default.
• W2262585804 cites W1983392832 @default.
• W2262585804 cites W2186220306 @default.
• W2262585804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11025590" @default.
• W2262585804 hasPublicationYear "2000" @default.
• W2262585804 type Work @default.
• W2262585804 sameAs 2262585804 @default.
• W2262585804 citedByCount "22" @default.
• W2262585804 countsByYear W22625858042012 @default.
• W2262585804 countsByYear W22625858042013 @default.
• W2262585804 countsByYear W22625858042014 @default.
• W2262585804 countsByYear W22625858042015 @default.
• W2262585804 countsByYear W22625858042016 @default.
• W2262585804 countsByYear W22625858042017 @default.
• W2262585804 countsByYear W22625858042019 @default.
• W2262585804 crossrefType "journal-article" @default.
• W2262585804 hasAuthorship W2262585804A5008633354 @default.
• W2262585804 hasAuthorship W2262585804A5009381933 @default.
• W2262585804 hasAuthorship W2262585804A5011435773 @default.
• W2262585804 hasAuthorship W2262585804A5017814449 @default.
• W2262585804 hasAuthorship W2262585804A5021045480 @default.
• W2262585804 hasAuthorship W2262585804A5045043807 @default.
• W2262585804 hasAuthorship W2262585804A5048644406 @default.
• W2262585804 hasAuthorship W2262585804A5060211572 @default.
• W2262585804 hasAuthorship W2262585804A5077344066 @default.
• W2262585804 hasAuthorship W2262585804A5078109432 @default.
• W2262585804 hasConcept C120665830 @default.
• W2262585804 hasConcept C121332964 @default.
• W2262585804 hasConcept C126322002 @default.
• W2262585804 hasConcept C141071460 @default.
• W2262585804 hasConcept C151032500 @default.
• W2262585804 hasConcept C2776863199 @default.
• W2262585804 hasConcept C2778461978 @default.
• W2262585804 hasConcept C2778837598 @default.
• W2262585804 hasConcept C2780007613 @default.
• W2262585804 hasConcept C2780076729 @default.
• W2262585804 hasConcept C2780959883 @default.
• W2262585804 hasConcept C61511704 @default.
• W2262585804 hasConcept C71924100 @default.
• W2262585804 hasConcept C72563966 @default.
• W2262585804 hasConcept C88879693 @default.
• W2262585804 hasConcept C90924648 @default.
• W2262585804 hasConceptScore W2262585804C120665830 @default.
• W2262585804 hasConceptScore W2262585804C121332964 @default.
• W2262585804 hasConceptScore W2262585804C126322002 @default.
• W2262585804 hasConceptScore W2262585804C141071460 @default.
• W2262585804 hasConceptScore W2262585804C151032500 @default.
• W2262585804 hasConceptScore W2262585804C2776863199 @default.
• W2262585804 hasConceptScore W2262585804C2778461978 @default.
• W2262585804 hasConceptScore W2262585804C2778837598 @default.
• W2262585804 hasConceptScore W2262585804C2780007613 @default.
• W2262585804 hasConceptScore W2262585804C2780076729 @default.
• W2262585804 hasConceptScore W2262585804C2780959883 @default.
• W2262585804 hasConceptScore W2262585804C61511704 @default.
• W2262585804 hasConceptScore W2262585804C71924100 @default.

• next